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IMMUNE NEONATAL THROMBOCYTOPENIA – REVIEW
TROMBOCITOPENIA NEONATAL IMUNE – REVISÃO 
ABSTRACT
 
Introduction: Thrombocytopenia is the most frequent hematological change in the neonatal period, with immune thrombocytopenia 
as the main cause of moderate-to-severe thrombocytopenia in apparently healthy newborns. Immune thrombocytopenia in the fetus or 
newborn may result from platelet alloantibodies against paternal antigens inherited by the fetus (alloimmune thrombocytopenia) or platelet 
autoantibodies due to maternal autoimmune disease (autoimmune thrombocytopenia).
Objetives: To review published literature about immune thrombocytopenia in newborns, including the latest advances in pathogenesis, 
diagnosis, treatment, and prevention.
Results: Neonatal alloimmune thrombocytopenia is the most common cause of severe thrombocytopenia and intracranial hemorrhage 
in term neonates. Clinical presentation varies from mild thrombocytopenia to life-threatening bleeding and death. As maternal screening 
is not routinely performed, most cases are diagnosed in the first child. Despite intensive research, a consensus strategy for prevention and 
treatment of the condition is lacking. Diagnosis of neonatal autoimmune thrombocytopenia is usually apparent from maternal medical history 
and thrombocytopenia. Although maternal immune thrombocytopenic purpura does not carry a high risk of perinatal hemorrhage, it may 
lead to thrombocytopenia in the newborn, mostly mild-to-moderate. Clinical presentation varies from no symptoms to mucocutaneous signs 
of thrombocytopenia and may persist for weeks to months requiring long-term monitoring. 
Conclusions: Fetal and Neonatal alloimmune thrombocytopenia can cause severe disease in the affected fetus or newborn. Facing the 
lack of routine antenatal screening, the strategies currently proposed for pregnancies at risk. We also discussed the latest research and 
therapies in development, aiming at potential improvements in diagnosis, treatment, and prevention of this disease. Neonatal autoimmune 
thrombocytopenia may cause long-lasting low platelet count, that need regular checking.
Keywords: autoimmune thrombocytopenia; alloimmune thrombocytopenia; newborn
RESUMO
Introdução: Trombocitopenia é a alteração hematológica mais frequente no período neonatal, sendo trombocitopenia imune a principal 
causa de trombocitopenia moderada a grave em recém-nascidos aparentemente saudáveis. O desenvolvimento de  trombocitopenia imune 
no feto ou no recém-nascido pode dever-se à passagem transplacentária de anticorpos plaquetários maternos, nomeadamente aloanticorpos 
dirigidos a antigénios paternos herdados pelo feto (aloimune) ou autoanticorpos sintetizados por patologia autoimune materna (autoimune). 
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Objetivos: Rever a literatura pulicada até à data sobre o tema, 
incluindo os últimos avanços sobre patogénese, diagnóstico, 
tratamento e prevenção de trombocitopenia imune em recém-
nascidos.
Resultados: Trombocitopenia neonatal aloimune é a causa mais 
comum de trombocitopenia grave e hemorragia intracraniana 
em recém-nascidos de termo. A apresentação clínica varia entre 
trombocitopenia ligeira isolada e hemorragia intracraniana letal. 
Dado que o rastreio pré-natal não é efetuado por rotina, a maioria 
dos casos são diagnosticados no primeiro filho. Apesar de intensa 
investigação, não existe atualmente uma estratégia consensual de 
prevenção e tratamento da condição. 
Deve existir suspeita de trombocitopenia neonatal autoimune 
em presença de história materna sugestiva ou trombocitopenia 
materna. Púrpura trombocitopénica imune materna não comporta 
um risco elevado de hemorragia perinatal, embora possa originar 
trombocitopenia –na maioria dos casos, ligeira a moderada − no 
recém-nascido. A apresentação clínica varia entre ausência de 
sintomas a presença de sinais mucocutâneos de trombocitopenia e 
pode persistir durante semanas a meses, requerendo monitorização 
a longo prazo. 
Conclusões: A trombocitopenia aloimune fetal e neonatal é causa 
de doença grave no feto ou no recém-nascido afetado. Dada a 
inexistência de rastreio pré-natal de rotina, é efectuada a revisão 
das estratégias propostas atualmente para as gestações de risco, 
assim como a discussão da investigação mais recente e das terapias 
em desenvolvimento, cujo objectivo é melhorar o diagnóstico, 
tratamento e prevenção dessa doença. A trombocitopenia neonatal 
autoimune pode levar a baixa contagem de plaquetas persistente, 
sendo necessário um controlo regular.
Palavras-chave: trombocitopenia aloimune; trombocitopenia 
autoimune; recém-nascido
INTRODUCTION
Neonatal thrombocytopenia is defined by platelet count below 
150,000/µL and can be subdivided into mild (100,000 to 150,000/
µL), moderate (50,000 to 99,000/µL), and severe (<50,000/µL), the 
latter being associated with an increased risk of bleeding resulting 
in morbidity or death.1 However, the largest study conducted using 
neonatal platelet count has recently shown that values between 
100,000 and 150,000/µL are more common among newborns 
than children. Platelet count increases with advanced postnatal 
age, thus prematurity is an important risk factor for neonatal 
thrombocytopenia.2,3 Other reported predisposing factors for 
neonatal thrombocytopenia include preterm birth, sepsis, asphyxia, 
intrauterine growth restriction, and necrotising enterocolitis.1
Altough thrombocytopenia is a rare event in the general newborn 
population, it occurs in 18−35% of neonates admitted to neonatal 
intensive care units.2 
The reported incidence of neonatal thrombocytopenia is 1.8 per 
1,000 live births.1 
Prevalence of cutaneous bleeding in thrombocytopenic neonates 
has been reported to be as high as 81%.2 Mortality rate in these 
newborns is significantly related to the underlying pathological 
condition and thrombocytopenia severity. 
The most common pathophysiological mechanism is increased 
platelet destruction, either by immunological cause or peripheral 
consumption.1 
Immune neonatal thrombocytopenia is due to placental crossing of 
maternal antibodies, which destroy fetal and/or neonatal platelets. It 
is a common cause of early thrombocytopenia in healthy newborns 
(before 72 hours of life) and can be subdivided into alloimmune or 
autoimmune.1,3
OBJECTIVES
The aim of this study was to review recent evidence on neonatal 
immune thrombocytopenia, namely alloimmune and autoimmune 
thrombocytopenia. Pathogenesis, diagnosis, and treatment are 
discussed, as well as prevention and current medical research. 
Literature search included articles published over the last ten years in 
English and Portuguese retrieved from several databases, including 
PubMed.
DEVELOPMENT
Alloimmune thrombocytopenia
Neonatal alloimmune thrombocytopenia (NAIT), also referred 
to as fetal and neonatal alloimmune thrombocytopenia (FNAIT), 
is the result of maternal antibodies directed towards fetal and 
neonatal platelets. NAIT is the main cause of early and severe 
thrombocytopenia, as well as intracranial hemorrhage (ICH) in term 
neonates.3-6 
Epidemiology
NAIT incidence is 0.5–1.5 per 1,000 births. However, as mild cases 
may go undetected and most severe cases can lead to intrauterine 
death, the real incidence may be higher.3 
Recent studies have shown a severe NAIT incidence of 63 per 
100,000, with six per 100,000 ICH cases, all reported in utero. A 
recent study by Tiller et al. indicated that most ICH cases occur before 
the 28th week of gestation.6 A 2014 systematic review of prospective 
studies reported a  0.15% incidence of severe thrombocytopenia in 
the general newborn population, with NAIT diagnosed in one-quarter 
of these patients.1  
Pathophysiology
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NAIT is triggered when fetal platelets express a paternally-inherited 
antigen that is lacking in the mother (human platelet antigen, HPA). 
As a result, the mother develops immunoglobulin G (IgG) antiplatelet 
antibodies against the “foreign” antigen, which cross the placenta 
and destroy fetal platelets containing the paternal antigen.1,3
Two mechanisms have been proposed to explain maternal 
alloimmunization: maternal exposure to HPA on fetal platelets due 
to fetomaternal bleeding (most frequent during delivery) and/or 
maternal exposure to β-3 integrin on placental syncytiotrophoblast 
cells during pregnancy.4,7 
HPAs are the result of single nucleotide polymorphisms in the gene 
encoding any of the main glycoproteins located on platelet surface, 
particularly glycoprotein (GP) IIb/IIIa. Antigen epidemiology varies 
according to ethnic group.3 In the Caucasian population, 85% of 
immunizations are caused by alloantibodies against HPA 1a.6 Only 
approximately 2% of Caucasians are HPA-1a-negative, with anti-HPA-
1a antibodies detected in about 10% of HPA-1a-negative pregnant 
women. HPA-5b antigen is the second most common platelet antigen 
in the Caucasian population, while HPA-4 antigen system is most 
frequent in the Asian population.4 
The mother of an affected newborn is asymptomatic and has normal 
platelet count, although personal or family history of previously 
affected pregnancies may be present.1 
NAIT severity may be affected by several factors:
• Pregnancy order – Evidence from retrospective studies suggest 
that in most cases the second pregnancy is more severely 
affected than the first. Repeated immune stimulation results 
in strong maternal immunization against fetal HPA-1a platelet 
antigens.8 
• Maternal HPA-1a antibody values – Low and stable maternal 
HPA-1a antibody levels appear to be associated with a low 
NAIT risk, while high and rising levels are predictive of neonatal 
thrombocytopenia.4 
• Intracranial hemorrhage in previous pregnancies – Fetal 
ICH due to alloimmune thrombocytopenia increases the 
probability of fetal ICH in subsequent pregnancies. About half 
of cases occur before 28 weeks of gestation and the risk of 
recurrent hemorrhage in a subsequent pregnancy is as higher 
as earlier in index gestation ICH occurred.4
• Type of platelet antigen – HPA-1a alloimmunization causes 
severe disease, while HPA-5b alloimmunization is associated 
with less severe condition.4
• Human leukocyte antigen (HLA) type: HPA-1 antigenic system 
is defined as an amino acid change at residue 33 of the mature 
glycoprotein IIIa (integrin β-3). HPA-1a peptide presentation 
and subsequent anti-HPA-1a alloantibody production are 
associated with a particular HLA: DRB3*01:01. In 90% of HPA-
1a fetomaternal alloimmunization cases, the mother carries 
this HLA-class II molecule. Some authors suggest that HLA 
DRB4*01:01 also plays a role in HPA-1a peptide presentation 
and the combination of both DRB3*01:01 and DRB4*01:01 is 
associated with NAIT, affecting response to prenatal treatment 
with intravenous (IV) immunoglobulin.6,9 
• Presence of anti-HPA-1a antibodies of α-v β-3 subtype 
specificity in maternal serum – α-v β-3-specific anti-HPA-1a 
antibodies induce endothelial cell apoptosis, which affects fetal 
vessel wall integrity, a critical factor in fetal ICH development, 
even in absence of thrombocytopenia. This occurs by inhibition 
of angiogenic signaling, inducing endothelial cell apoptosis 
and decreasing blood vessel density in the brain and retina, 
potentially explaining why ICH does not occur in all severe fetal 
thrombocytopenia cases. ICH can appear in occasional cases 
with normal fetal platelet count.4 
Clinical findings and management
Clinical findings in affected newborns depend on thrombocytopenia 
severity. Findings may include petechiae, bruising, and bleeding in 
neonates with moderate-to-severe thrombocytopenia. Bleeding risk 
is highest within the first 96 hours of life.1,10 
NAIT diagnosis should be considered in neonates presenting 
with severe thrombocytopenia at birth or in the first 24−48 hours 
of life, particularly in absence of other risk factors, clinical signs, 
or abnormalities in physical examination.1,3 Additionally, diagnosis 
should also be considered in ill-appearing infants, especially if severe 
thrombocytopenia seems out of proportion to the clinical illness or 
persists despite clinical improvement.1
ICH is the most severe complication of NAIT. It occurs in 
approximately 10−20% of affected newborns − 25−50% of these in 
utero (mostly before 28 weeks of gestation) – and is fatal in 59% of 
cases.1,3,4,6,8,11 Association of severe neonatal thrombocytopenia with 
parenchymal, rather than intraventricular, ICH is highly suggestive of 
NAIT.3 Extracranial fetal hemorrhage is extremely rare.4 Knight and 
colleagues estimated that one in every 25 infants with FNAIT die 
antenatally through miscarriage, stillbirth, or pregnancy interruption, 
and an estimated one in every 12 infants dies or becomes severely 
disabled before the age of one year. The authors also estimated that 
this occurs in approximately one in every 100,000 total births.12 
Neonatal platelet count is often less than 100,000/µL and typically 
decreases within the first few days after birth then increasing until 
four weeks, as antibody levels decline.1 
Current recommendations state that all neonates with platelet 
count bellow 50,000/µL in the first days of life should be investigated 
for NAIT.3
When NAIT is suspected, blood should be collected from the 
mother and father and submitted to antigen screening (HPA). Positive 
cases show maternal plasma antibodies directed against specific 
paternal platelet antigens. If blood cannot be collected from parents, 
neonatal serum may be screened for presence of antiplatelet 
antibodies. However, if antibody concentration in the newborn is 
low, it may lead to false negative results. It remains unclear whether 
a correlation exists between antibody affinity and severity of disease. 
These evaluations should be performed in an experienced reference 
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laboratory, with required technology and resources. As antibodies 
can be difficult to detect in samples collected during delivery, follow-
up serology tests should be performed when clinical diagnosis of 
NAIT is suspected.1,3 NAIT is thus confirmed by identifying maternal 
antiplatelet antibodies.1 
Cranial ultrasound should be performed as soon as the condition is 
suspected to exclude prenatal ICH, as findings will dictate the aproach 
to the affected infant and mother’s future pregnancies. The clinical 
course is usually short, often resolving within two weeks. However, 
platelet count should be frequently monitored until reaching normal 
values to confirm diagnosis.1,3
Current management decisions are based on clinical experience, 
as available data is still insufficient to establish an evidence-based 
management approach.1 
Platelet transfusions are commonly administered in neonatal 
thrombocytopenia to reduce estimated bleeding risk by 20–30%. 
However, differences in hemostasis and underlying disease hamper 
extrapolation of platelet transfusion practices from other populations 
to neonates. It is therefore important to identify neonates at risk of 
bleeding who may benefit from platelet transfusion, weighing if the 
procedure can exacerbate common neonatal complications. Sparger 
et al. reported that illness severity influenced transfusion decisions. 
However, thrombocytopenia severity did not correlate with ICH risk 
and platelet transfusion did not reduce this risk. Elisabeth Resch 
and colleagues concluded that mortality was not associated with 
severity of neonatal thrombocytopenia, but increased with platelet 
transfusion number, as it may reflect the severity of underlying 
disease or extreme prematurity.2 
Random donor platelet transfusion is considered the first line of 
therapy, based on recent data showing that a large proportion of 
NAIT infants respond to the procedure.1 If the newborn is clinically 
stable and does not have ICH, platelets are usually administered 
when platelet count is lower than 30,000/µL and in presence of 
bleeding signs. In preterm or clinically unstable infants, platelet 
transfusion is usually administered when platelet count is lower than 
50,000/µL during the first week of life. In evidence of ICH, the goal is 
to maintain platelet count above 50−100,000/µL.1,3
Several platelet transfusion options may be considered:1,3 
 — Use of maternal platelet concentrate reduces the amount of 
antiplatelet antibody-containing serum but may delay the transfusion 
process, since it can take up to 12−24 hours to collect and process 
cells. However, it is preferable to washed platelets, since the washing 
process damages cells. Platelets should be irradiated to avoid graft-
versus-host disease.
 — In infants with severe thrombocytopenia or hemorrhage, 
random donor platelets should be initially used, as they have proven 
effective in rapidly increasing platelet count. However, survival of 
incompatible platelets may be short. In the meantime, action can be 
taken to acquire maternal platelets for future transfusions. 
 — Alternatively, donor platelets typed and matched to maternal 
cells can be used to exclude the offending platelet antigen. However, 
unless the infant has a NAIT sibiling and this was anticipated, it is 
unlikely that matched platelets are available in an emergency setting.
 — If transfusion of ABO-incompatible platelets is required, plasma 
component should be reduced to avoid potential hemolysis.
 — Administration of HPA-1a-negative/HPA-5b-negative platelet 
concentrates is an option, although costly and not generally available. 
When a neonate is born to a mother with a previously NAIT-affected 
pregnancy, genotypically matched platelets should be available in 
the blood bank at time of delivery and should represent the first-line 
treatment if infant is thrombocytopenic.3
However, it is important to remember that some NAIT infants fail 
to respond to random donor platelets and other therapies. For this 
reason, the blood bank should be immediately warned about a 
suspected NAIT infant, and measures should be taken to secure an 
antigen-negative platelet source as soon as possible. Platelets from 
the mother and HPA-1b1b or HPA-5a5a donors are compatible in 
more than 90% of cases.3 
If NAIT is confirmed or strongly suspected, intravenous 
immunoglobulin (IVIg) (1 g/kg per day for two consecutive days 
or 400 mg/kg per day for three to four days) may be administered 
immediately following platelet transfusion to increase patient’s 
own platelets and potentially protect transfused platelets. 
Because in NAIT platelet counts usually fall after birth, IVIg may be 
administered when platelet count is between 30−50,000/µL in a 
stable neonate.1,3 Although intravenous methylprednisolone (1 mg 
every eight hours for one to three days) has been used as additional 
therapy, its effectiveness has not been proven, with some authors 
considering it in cases of persisting refractory and life-threatening 
thrombocytopenia.1
Fetal and neonatal alloimmune thrombocytopenia is analogous 
to fetal and neonatal anaemia caused by anti-red cell antibodies in 
hemolytic disease of the fetus and newborn. In contrast, in FNAIT first 
pregnancies are often severely affected and diagnosis is usually made 
at birth of the first affected infant. Therefore, the debate about the 
usefulness of antenatal screening for the condition persists.12 Tiller 
et al. estimated that testing for FNAIT only in presence of clinical 
symptoms misses 86% of cases.11 Another study showed that timely 
FNAIT diagnosis was not performed in 15% of neonates born with 
severe thrombocytopenia, with severe consequences for subsequent 
pregnancies, including ICH.6 Women giving birth to NAIT infants 
should be followed for all future pregnancies in a perinatal referral 
center, as recurrence rate is high and they can benefit from prenatal 
treatment at those centers.3 Maternal treatment with weekly IVIg 
infusions, with or without steroids, may be indicated, as well as fetal 
therapy with platelet transfusion in utero (weekly or immediately 
before delivery); timed nearterm delivery (by labor induction or 
cesarean delivery) and birth in a perinatal center with immediate 
availability of matched platelets are other measures that should be 
taken.6,13-17 In families with an affected fetus or infant, recurrence 
rate is as high as 75−90%. Thrombocytopenia in the second affected 
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newborn is equally or more severe than in the first.1
Other therapeutic alternatives are being studied to reduce newborn 
exposure to blood products, including hematopoietic growth factors 
and thrombopoietin.18 Current medical research is focused on FNAIT 
prevention, namely in development of biological drugs. 
One of investigated drugs is purified hyperimmune anti-HPA-1a 
Ig, from plasma collected from HPA-1a-immunized women with a 
previous FNAIT-complicated pregnancy. The hyperimmune anti-HPA-
1a IgG is used for disease prevention through antibody-mediated 
immune suppression. The underlying concept was to apply the same 
prophylactic principle by which hyperimmune anti-D IgG has been 
used for hemolytic disease prevention. The drug is administered 
within the first six hours after delivery to negative HPA-1a women 
with antigen-positive newborns. This resulted from a European 
project started in 2011 (www.profnait.eu) and approved by the Food 
and Drug Administration (FDA) in December 2017. Drug’s licensing 
for clinical use is anticipated for 2020.19-22
It has been shown that neonatal Fc receptor (FcRn) regulates 
immunoglobulin G homeostasis and plays an important role in 
transplacental IgG transport. This receptor is expressed in placental 
syncytiotrophoblast. Recombinant monoclonal antibodies directed 
at FcRn are currently being investigated in animal models. They 
act by blocking receptor and preventing transplacental transport 
of alloantigens and represent a potential prenatal drug. However, 
further studies are required to confirm this hypothesis.23-25 
Another potential prenatal therapy under development is human 
recombinant high-affinity HPA-1a antibody, which competes with 
maternal alloantibodies for fetal platelet binding. This therapy has 
already been tested in volunteers, showing a platelet destruction 
reduction and survival increase. However, further studies are 
warranted regarding its benefits for the fetus.21,25
Autoimmune thrombocytopenia
Autoimmune thrombocytopenia is due to maternal autoantibodies 
reacting with antigens expressed on both maternal and neonatal 
platelets. This occurs in maternal autoimmune disorders, including 
imune thrombocytopenia purpura (ITP) and systemic lupus 
erythematosus.1,3,26
Autoimmune thrombocytopenia is estimated to occur in one to two 
of every 1,000 pregnancies.26 
Diagnosis is usually apparent from maternal medical history and 
thrombocytopenia. However, platelet count of affected mothers may 
be normal after a splenectomy or in cases of sufficient compensatory 
thrombopoiesis.1 
ITP mothers have an only 10% risk of having thrombocytopenic 
infants.13 Mothers of infants with unexplained neonatal 
thrombocytopenia should be investigated for presence of an 
autoimmune disorder, since neonatal thrombocytopenia can 
be the presenting sign. However, healthy women without 
history of autoimmune disorders may also develop gestational 
thrombocytopenia. This is considered a benign mild and transient 
form of ITP, with neonatal thrombocytopenia being a rare event.1 
Maternal splenectomy, maternal platelet count below 50,000/
µL at some time during pregnancy, and history of an older sibling 
with neonatal thrombocytopenia are risk factors associated with 
autoimmune neonatal thrombocytopenia.1,26,27 
Most affected infants seem healthy, as more than half of infants 
born to ITP mothers have either mild thrombocytopenia or normal 
platelet counts. However, a relevant minority of infants develops 
severe thrombocytopenia.27 Clinical signs are consistent with 
moderate-to-severe thrombocytopenia and include petechiae, 
bruising, and bleeding. Clinical manifestations are less severe than 
in alloimmune thrombocytopenia and ICH risk is lower than 1% and 
decreases between the third and fourth days of life.1,28
Platelet counts of infants born to ITP mothers often decrease 
sharply during the first days after birth, with nadir typically occurring 
between the age of two and five days. All infants with maternal history 
of autoimmune disorders should perform early postnatal platelet 
count, which should be monitored if below the normal range.1,3,13 If 
the neonate has mild thrombocytopenia, platelet count should be 
repeated within two to three days; if it is lower than 30,000/µL, first-
line treatment with IVIg should be provided.3 Asymptomatic infants 
with stable platelet counts above 30,000/µL may be discharged, with 
appropriate outpatient follow-up.1 
Cranial ultrasound should be performed to all infants with platelet 
count below 30,000/µL for ICH assessment.3
Importantly, neonatal thrombocytopenia secondary to maternal 
ITP may last for weeks to months, requiring long-term monitoring.3 It 
has recently been reported that antiplatelet antibody transfer from 
ITP mothers through breastfeeding (immunoglobulin-A type) can be 
associated with persistent neonatal thrombocytopenia (beyond four 
months) and resolve when breastfeeding is discontinued.1,3,29
Platelet transfusion is provided to infants with severe 
thrombocytopenia or clinical bleeding. However, transfusions may be 
ineffective since autoantibodies usually react with donor platelets, 
including from the mother. For this reason, some authors recommend 
administering IVIg after transfusion.1,3,27 
IVIg should be offered to infants with severe thrombocytopenia 
at a 1 g/kg dose, which may be repeated. Since it may last weeks 
to months, a second IVIg dose is sometimes required at four to six 
weeks of life.1,3 This treatment typically produces a rapid response. 
If thrombocytopenia is severe and persists after IVIg therapy, some 
clinicians consider administering a short course of prednisone (2 
mg/kg per day) or methylprednisolone (1 mg/kg twice a day for five 
days), although the efficacy of this approach has not been proven.1
History of neonatal thrombocytopenia in the previous infant 
represents the only reliable predictor of neonatal thrombocytopenia 
in ITP mothers. Type of delivery in ITP patients should be selected 
according to obstetric indication, avoiding interventions that may 
increase fetal bleeding risk.3
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CONCLUSIONS
FNAIT is the most frequent cause of severe isolated 
thrombocytopenia in neonates, and ICH its most devastating 
outcome.30 In absence of routine antenatal screening, most diagnoses 
are performed when the fetus or newborn are already affected.31 
For this reason, implementation of a routine antenatal screening 
program has been widely discussed over the last decade, aiming at 
HPA typing and detection of pregnant women at risk, similarly to Rh 
immunization screening instituted in the 1960s. However, despite 
several published studies supporting screening cost-effectiveness, 
no European or American country has adopted this strategy to date, 
one of the main arguments being the lack of consensus regarding 
the optimal treatment for pregnant women at risk.31-33 Proposed 
intervention strategies for screening-positive pregnancies include 
maternal IVIg infusions (with or without steroids), timed nearterm 
delivery, and birth in a perinatal center with immediate availability of 
matched platelets.13-15,34,35 
Among other aspects, current research aims to better understand 
the mechanisms involved in ICH development in the context of 
alloimmune thrombocytopenia, such as angiogenesis interference via 
cross-reaction of antiplatelet antibodies with α-V β-3 integrin present 
in endothelial cells. Detection of maternal anti-α-V β-3 antibodies 
may be crucial for ICH prevention and diagnosis.17 New therapies 
are also under investigation, namely human Ig-specific anti-HPA-1a 
immunoglobulins, recombinant monoclonal antibodies directed at 
FcRn, and recombinant anti-HPA-1a monoclonal antibodies.36,37
Neonatal autoimmune thrombocytopenia does not carry a 
serious risk of perinatal bleeding, but may cause moderate neonate 
thrombocytopenia persisting for weeks to months and requiring 
long-term monitoring.38
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